Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | ESR1 | P03372 | 2/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | TACR2 | P21452 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TST | Q16762 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700041 | 1.00 | PTGS2 (0.67) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL9698501 | 1.00 | PTGS2 (0.67) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL2047392 | 1.00 | PTGS2 (0.67) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL2049841 | 1.00 | PTGS2 (0.67) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL2046991 | 1.00 | PTGS2 (0.67) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL4065606 | 0.98 | PTGS2 (0.63) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL20335366 | 0.95 | PTGS2 (0.65) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL29946510 | 0.93 | PTGS2 (0.55) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL2048075 | 0.93 | PTGS2 (0.55) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL11222681 | 0.89 | PTGS2 (0.57) | PTGS2CYP3A4ESR1ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344080-B2 | Catalyst for olefin polymerization and method of preparation thereof | WANG LICAI (CN) | 2013-01-01 | — | — | US | disclosed |
| US-20110301385-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD OF PREPARATION THEREOF | WANG LICAI (CN) | 2011-12-08 | — | — | US | disclosed |
| US-7964678-B2 | Comprises titanium/magnesium-1,4-diether [2,2'-dialkoxy-1,1'-biphenyl, 2,2'-dialkoxy-1,1'-binaphthalene, 10,10'-dialkoxy-9,9-biphenanthrene complex, organoaluminum compound, and organosilicon compound; molecular weight control | WANG LICAI | 2011-06-21 | — | — | US | disclosed |
| US-20080161513-A1 | Catalyst for Olefin Polymerization and Preparation Thereof and Polymerization Process | YINGKOU XIANGYANG CATALYST CO., LTD. (CN) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301385-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD OF PREPARATION THEREOF | PPOX, CAT, POR | PTGS2 400/4885CYP3A4 106/4885ESR1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.